Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asparagine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLI1 | P08151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.35 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL2484608 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL27708267 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL28801809 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL28252029 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL2484607 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL2537696 | 1.00 | NOS2 (0.41) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL537634 | 0.94 | NOS2 (0.37) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL2440846 | 0.94 | NOS2 (0.37) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL4607285 | 0.94 | NOS2 (0.37) | NOS2NOS3NOS1GRIK1GRIK2 | |
| Asparagine SCHEMBL4354914 | 0.94 | NOS2 (0.37) | NOS2NOS3NOS1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567559-A | Peptide with anti-forgetting activity and preparation method and application thereof | 安琪生物科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117486971-A | Antioxidant peptide, walnut peptide and preparation method and application thereof | 安琪生物科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023080159-A1 | LIGAND-BOUND NUCLEIC ACID COMPLEX | レナセラピューティクス株式会社 | 2023-05-11 | — | — | WO | disclosed |
| US-20210024593-A1 | MODIFIED HEAT SHOCK PROTEINS | RUBICON BIOTECHNOLOGY LLC | 2021-01-28 | — | — | US | disclosed |
| WO-2020149287-A1 | EDIBLE OIL/FAT COMPOSITION AND METHOD FOR PRODUCING SAME | 不二製油グループ本社株式会社 | 2020-07-23 | — | — | WO | disclosed |
| EP-3672985-A2 | MODIFIED HEAT SHOCK PROTEINS | Rubicon Biotechnology LLC (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040887-A2 | MODIFIED HEAT SHOCK PROTEINS | RUBICON BIOTECHNOLOGY LLC (US) | 2019-02-28 | — | — | WO | disclosed |
| CN-102481332-A | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD | 2012-05-30 | — | — | CN | disclosed |
| US-8044230-B2 | Hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing the active compound | INTERVET INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080146640-A1 | Water-Soluble Prodrugs of Chloramphenicol, Thiamphenicol, and Analogs Thereof | SCHERING-PLOUGH LTD. (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1581557-A2 | METASTIN DERIVATIVES AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005080551-A2 | STEM CELLS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004060264-A2 | METASTIN DERIVATIVES AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0973914-A1 | PROTEINS HAVING LECITHIN-CHOLESTEROL ACYLTRANSFERASE-LIKE ACTIVITY, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-26 | — | — | EP | disclosed |
| US-5958886-A | FOR TRANSPORTING EXOGENEOUS CARNITINE ACROSS CELL MEMBRANES AND INTESTINAL MUCOSAE IN MAMMALS TO REDUCE CARNITINE DEFICIENCY | SIGMA-TAU PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1998046767-A1 | PROTEINS HAVING LECITHIN-CHOLESTEROL ACYLTRANSFERASE-LIKE ACTIVITY, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| WO-1992010518-A1 | PURIFIED SLIT PROTEIN AND SEQUENCE ELEMENTS THEREOF | YALE UNIVERSITY (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146640-A1 | Water-Soluble Prodrugs of Chloramphenicol, Thiamphenicol, and Analogs Thereof | TREH, ADH5, CES2 | NOS2 286/4885NOS3 335/4885NOS1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.